Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines.
about
Primary prevention and treatment of venous thromboembolic events in patients with gastrointestinal cancers - ReviewTransitions in the Prophylaxis, Treatment and Care of Patients with Venous ThromboembolismVenous thromboembolism in cancer patients: an underestimated major health problemThromboprophylaxis guidelines in cancer with a primary focus on ambulatory patients receiving chemotherapy: a review from the Southern Network on Adverse Reactions (SONAR)What is the Best Treatment for a Cancer Patient with Thrombosis?Guidance for the prevention and treatment of cancer-associated venous thromboembolismDifferential co-expression analysis of venous thromboembolism based on gene expression profile dataCanadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis.Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment.Safety of anticoagulation in thrombocytopenic patients with hematologic malignancies: A case series.Analysis of anticoagulation strategies for venous thromboembolism during severe thrombocytopenia in patients with hematologic malignancies: a retrospective cohort.Deep Vein Thrombosis of the Upper Extremity.Venous thromboembolism in cancer patients: a call for more awareness.2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism.Implementing thrombosis guidelines in cancer patients: a review.Cancer-associated thrombosis: an overviewImproved compliance with venous thromboembolism pharmacologic prophylaxis for patients with gynecologic malignancies hospitalized for nonsurgical indications did not reduce venous thromboembolism incidence.Guidelines for treatment and prevention of venous thromboembolism among patients with cancer.Epidemiology, clinical profile and treatment patterns of venous thromboembolism in cancer patients in Taiwan: a population-based study.Primary venous thromboembolism prophylaxis in patients with solid tumors: a meta-analysisPerioperative changes in pro and anticoagulant factors in prostate cancer patients undergoing laparoscopic and robotic radical prostatectomy with different anaesthetic techniques.Cancer therapy and cardiovascular risk: focus on bevacizumab.Impact of cancer on the effectiveness of cardiac Troponin I to predict right ventricular dysfunction in acute pulmonary embolism.Fatal Events in Cancer Patients Receiving Anticoagulant Therapy for Venous Thromboembolism.Preoperative Chemoprophylaxis is Safe in Major Oncology Operations and Effective at Preventing Venous Thromboembolism.Venous thrombosis and cancer: from mouse models to clinical trials.Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients.Prospective Study on the Incidence of Postoperative Venous Thromboembolism in Korean Patients with Colorectal Cancer.Characteristics of Venous Thromboembolism in Pancreatic Adenocarcinoma in East Asian Ethnics: A Large Population-Based Observational Study.A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment.Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis.Iliofemoral Venous Thrombosis Mainly Related to Iliofemoral Venous Obstruction by External Tumor Compression in Cancer Patients.New oral anticoagulants and the cancer patient.Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis.Analysis of clinical factors affecting the rates of fatal pulmonary embolism and bleeding in cancer patients with venous thromboembolism.Coagulation and cancer: biological and clinical aspects.Thromboembolic disease in cancer patients.Improving surgical outcomes in renal cell carcinoma involving the inferior vena cava.Low-molecular-weight heparins for the prevention of recurrent venous thromboembolism in patients with cancer: A systematic literature review of efficacy and cost-effectiveness.Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: Focus on Drug Therapy.
P2860
Q26753853-3F65B231-47FF-47A4-ABA5-822DCB08A5ECQ26775157-5CC70F42-03EA-4C25-951B-FA7C2E2B914EQ26852015-5B3B0A10-7CBC-46A1-AE7A-F4291D195056Q26995284-5896438A-DD4B-4484-9FE2-32E508105E6EQ27009514-D60BFDF3-8390-4C5E-9E43-C63C732F9776Q28069131-7855F96B-AB14-419F-9DCF-EA1FD43CC5E5Q31107077-CA0146B9-906F-4C0E-8729-1ED7367199BBQ33422297-30178E7D-363C-499F-8048-D6D0D74D8976Q33422300-4F954321-CD03-48BC-B931-3A4284F7347BQ33429840-F45C3882-6025-4E60-BBB8-4A4F17C2513CQ33440816-FEA6BDB7-1A84-4BDB-B764-26300CB3DF06Q33635174-C5F8E40B-76C3-4467-AC58-55501DC0AE11Q33982637-2ADE9997-FFC0-4859-9A77-8DA53A248F90Q34436061-803A3CEA-F984-4A02-BF9A-9C0180264FA6Q34463482-21236739-7EC6-473D-9F2B-909EFD1841C5Q34655217-C07F0884-181B-495A-BD05-658E95493120Q34747122-BA73A819-02ED-4EA4-B088-C780ABC8FE3AQ35174604-EB03951F-7730-4DF9-8695-66BF2686CB06Q35552333-4229725B-D0B0-4D0D-AE34-7B58B7634AF1Q35594902-1CF87622-BB0A-4802-AE3D-7C22A9051C15Q35605876-8A96D9C6-651E-47D8-B9E3-77143186D048Q35703835-2F88F553-A11B-4924-AC13-AC7BE8253281Q36051692-50E5BA32-06FB-4179-BC53-FF8A8B7C3817Q36195033-A66E10AB-9ECF-44E9-95FF-0AE43A7E6E94Q36510392-2074671D-0C7A-47C6-8A8A-F12998FF36C3Q36636558-A66CC413-E69C-443E-AD5F-EC6579BA722BQ36839479-7ABDF411-E1DB-44D6-A2F4-6D6CE861CB04Q37097499-1B4C5B62-1C13-416D-BA9C-9F4C02902CA1Q37206411-06629E49-AEB3-40D5-842B-02E47D39C4C6Q37293267-E93DAE65-8D81-43C3-B0A0-1837460AB4B2Q37404403-F848C6FE-F1F3-4E89-ADD2-9DCA911C32FFQ37504333-03CFDF0C-76E4-48D5-A5FE-9B30C0CFF03FQ37519054-03D0DD30-C61B-4882-B5AD-7A1AC6E5E5E6Q37587205-2D5B62D6-6386-4EEC-98AE-27D5AE41B006Q37588677-01CE2D62-25B2-4828-A52F-3147D4A23D8EQ38070918-66A6F179-3C1E-47EF-A831-9E8F56A6A408Q38083556-63D70509-B58D-4766-B448-111D14086292Q38162922-8DF0F3BC-57EF-407C-A25A-4B074423C360Q38600392-1634472A-28A5-4A65-A372-77BCECCE4B8FQ38686333-EBB0978B-3C30-4953-A4A4-157A5DE5CF4A
P2860
Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Management of venous thromboem ...... Clinical Practice Guidelines.
@ast
Management of venous thromboem ...... Clinical Practice Guidelines.
@en
Management of venous thromboembolism
@nl
type
label
Management of venous thromboem ...... Clinical Practice Guidelines.
@ast
Management of venous thromboem ...... Clinical Practice Guidelines.
@en
Management of venous thromboembolism
@nl
prefLabel
Management of venous thromboem ...... Clinical Practice Guidelines.
@ast
Management of venous thromboem ...... Clinical Practice Guidelines.
@en
Management of venous thromboembolism
@nl
P2093
P356
P1433
P1476
Management of venous thromboem ...... Clinical Practice Guidelines.
@en
P2093
ESMO Guidelines Working Group
P304
P356
10.1093/ANNONC/MDR392
P478
22 Suppl 6
P577
2011-09-01T00:00:00Z